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ABSTRACT
Introduction: Novel oral anticoagulants are
increasingly used for stroke prophylaxis in
patients with non-valvular atrial fibrillation.
While these agents offer a more predictable
pharmacokinetic profile, the lack of readily
available laboratory tests to monitor the level
of anticoagulation and absence of an antidote
or established therapies to reverse the
anticoagulant effect make management of
cases of over-anticoagulation challenging.
Case Report: In this case report an 87-year-old
man with a history of atrial fibrillation
presented with dabigatran excess in the setting
of life-threatening, acute renal and hepatic
failure. The authors review the use of
dabigatran in elderly patients, the available
data on management of patients with excess
anticoagulation, and the potential options for
reversal of the anticoagulation effect.
Conclusion: Further investigation into reliable
means of monitoring and reversing the
anticoagulant effect of dabigatran is crucial to
the management of such patients.
Keywords: Anticoagulants; Anticoagulation;
Atrial fibrillation; Dabigatran; Elderly; Renal
failure; Stroke
INTRODUCTION
Dabigatran etexilate is an oral direct thrombin
inhibitor approved for use as an alternative to
the vitamin K antagonist, warfarin, for stroke
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prophylaxis in patients with non-valvular atrial
fibrillation. Its predictable pharmacokinetic
profile provides significant user appeal since
routine monitoring of its anticoagulant effect
and dose titration are not required.
Furthermore, when compared with warfarin in
the Randomized Evaluation of the Long-Term
Anticoagulation Therapy (RE-LY) trial,
dabigatran was superior to warfarin in
preventing stroke and systemic embolization
at 150 mg twice-daily (1.11% versus 1.69% per
year, relative risk (RR) 0.66, 95% CI 0.53–0.82,
P\0.001 for superiority) and non-inferior to
warfarin at 110 mg twice-daily (1.53% versus
1.69% per year, RR 0.91, 95% CI 0.74–1.11,
P\0.001 for noninferiority) [1]. With respect
to bleeding, patients randomized to 110 mg
twice-daily experienced a lower rate of major
bleeding as compared to warfarin (2.71% versus
3.36% per year, P = 0.003), while those
randomized to 150 mg twice-daily had a
similar rate of major bleeding (3.11% versus
3.36%, P = 0.31). In a recent Mini-Sentinel
analysis of adverse post-marketing events,
dabigatran was not associated with a higher
risk of bleeding as compared to warfarin in
clinical use [2]. Despite a similar or superior
safety profile, two major disadvantages of
dabigatran include the lack of a reversal agent
and no validated, clinically available measure
to monitor anticoagulant activity, both of
which are critical to the care of patients
presenting with active bleeding. Here, the
authors report a case of an 87-year-old man
on dabigatran who presented with a
coagulopathy in the setting of acute renal and
hepatic failure. Given that 80% of dabigatran is
renally cleared, the authors caution clinicians
to carefully monitor renal function and adjust
dosing accordingly, especially in elderly
patients who are particularly susceptible to
asymptomatic changes in renal function.
CASE REPORT
An 87-year-old man with a history of atrial
fibrillation with CHA2DS2-VASc score of 5, heart
failure with preserved ejection fraction, and
hypertension presented to the emergency room
with weakness, decreased oral intake, and mild
cough. Consent for publication of this case
report was obtained from the patient’s wife. Five
months earlier, the patient started dabigatran
etexilate 150 mg orally twice-daily for
thromboembolic prophylaxis of atrial
fibrillation [which is the dose approved by the
US Food and Drug Administration (FDA) for
patients with normal or mildly impaired renal
function—the 110 mg dose is not available in
the US]. One week prior, the patient was seen by
his primary care physician for increased lower
extremity edema and found to have atrial
fibrillation with a rapid ventricular response
averaging 120 beats per minute. The serum
creatinine (Cr) at the time was measured at
1.20 mg/dL [estimated glomerular filtration
(eGFR) = 57 mL/min/1.73 m2 as reported by
the hospital laboratory based on the isotope
dilution mass spectrometry (IDMS)-traceable
Modification of Diet in Renal Disease [MDRD]
study equation]. The daily doses of verapamil,
metoprolol, and furosemide were increased
from 120 to 240, 25 to 100, and 40 to 60 mg,
respectively. Two days prior to presentation, the
patient fell while getting out of bed, but did not
seek medical attention. On the day of
admission, the patient was too weak to stand
and vomited three times, prompting his family
to seek emergency medical care. The last dose of
dabigatran was reportedly taken 2 days prior to
admission.
On initial evaluation, the axillary
temperature was 95.7 F, blood pressure
102/48 mmHg, ventricular rate 36 beats/min
with atrial fibrillation (Fig. 1), and oxygen
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saturation 96% on 2 L/min of supplemental
oxygen. On examination, the patient was ill
appearing but in no acute distress. The patient
had 10 cm of jugular venous distension with
monophasic waves and hepatojugular reflux.
There were bibasilar crackles present on lung
examination. Cardiac auscultation revealed a
bradycardic, irregular rhythm, normal first
heart sound with a physiologically split second
heart sound, and a III/VI systolic murmur
loudest at the upper sternal border. The
abdomen was benign without organomegaly.
There was 3? pitting edema of the extremities
with normal pulses bilaterally.
Upon arrival to the emergency department
2 L of intravenous (IV) normal saline and 1 mg of
IV glucagon were administered. A chest X-ray
revealed a right lower lobe infiltrate (Fig. 2),
cultures were obtained, and treatment was
initiated with ceftriaxone and levofloxacin.
Laboratory studies were notable for acute renal
failure and hepatic dysfunction, which likely
developed in the setting of septic shock from
pneumonia, potentially compounded by
recently increased diuretic therapy and
bradycardia in the setting of uptitration of
nodal blockade (Table 1; Fig. 3). In conjunction,
laboratory studies revealed electrolyte
disturbances, elevated serum lactate, and
profound coagulopathy (Table 1; Fig. 3). The
patient received 10 units of IV insulin, 50 g of
IV dextrose, 2 g of IV calcium gluconate, and
50 mEq of IV sodium bicarbonate to manage
hyperkalemia. Computed tomography of the
head, neck, and cervical spine did not show
evidence of acute hemorrhage or fracture.
On admission to the cardiac intensive care
unit, the heart rate was irregular at 48 beats/min
and the blood pressure was 90/50 mmHg. The
patient rapidly developed worsening hypoxia
and was placed on 70% oxygen at 35 L/min
delivered by high flow nasal cannula. During a
phlebotomy, the patient became acutely
unresponsive with a loss of palpable pulses.
Fig. 1 Admission electrocardiogram revealed atrial ﬁbrilla-
tion with a ventricular response rate of *36 beats/min.
The QRS morphology, duration, axis, voltage, and R wave
progression across the precordium are consistent with
nonspeciﬁc interventricular conduction delay and right axis
deviation
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The cardiac monitor revealed progressive
bradycardia to less than 30 beats/min. The
patient received approximately 2.5 min of
chest compressions with return of
spontaneous circulation, was intubated, and
placed on mechanical ventilation.
The patient did not demonstrate any overt
signs of active bleeding at any point during the
hospitalization. On admission, the hematocrit
was 43.5%, consistent with the patient’s
baseline value. In the setting of receiving a
total of 4.5 L of IV normal saline during the first
day of hospitalization, the hematocrit dropped
to a nadir of 33.9%, but gradually improved
without infusion of red blood cells to 38.3% on
day of discharge. However, taking into account
the history of a recent fall, need for central
venous access, and presence of multi-organ
failure in the elderly gentleman with possible
need for dialysis, the decision was made to
reverse the coagulopathy. A reversal strategy
was pursued that attempted to counteract both
dabigatran toxicity and the potential for
decreased hepatic synthesis of clotting factors
given concern for hepatic injury in the setting
of an acute transaminitis. The patient’s history
of heart failure and acute renal failure limited
the amount of high volume blood products that
could be administered and more concentrated
forms of coagulation factor replacement were
considered. A total of 4 units of fresh frozen
plasma (FFP), 15 mg of vitamin K (initially 5 mg
orally, then 10 mg IV), and 5,020 international
units (IU) of IV inactivated prothrombin
complex concentrates (PCC; Profilnine,
Grifols Biologicals, Inc, Los Angeles, CA, USA)
were administered on the first day of
hospitalization (Fig. 3). The prothrombin time
(PT) and partial thromboplastin time (PTT)
peaked in the first 24 h and then gradually
returned to normal (Fig. 3). Coagulopathy was
further measured using the thrombin time at 7,
24, and 26 h after admission and was [150 s
(normal range 15–30) at all three
measurements. A diluted thrombin time (one
part patient plasma to three parts normal
plasma) was measured at 24 and 26 h and
was 125.0 and 113.1 s, respectively (Table 1).
Fig. 2 Posteroanterior (a) and lateral (b) admission chest radiograph. Admission chest radiograph revealed a small right
pleural effusion with right basilar opacity consistent with pneumonia
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The hepatic transaminases and renal function
also peaked on the first day with an alanine
aminotransferase (ALT) of 4,590 U/L, aspartate
aminotransferase (AST) of 4,965 U/L, and Cr of
3.07 mg/dL (eGFR B20 mL/min/1.73 m2).
Thereafter, the patient’s Cr, transaminases,
and coagulation parameters trended downward
over the course of 10 days (Fig. 3).
The patient was stabilized and treated for
pneumonia in the intensive care unit for 7 days.
The patient was extubated on day 5, had no
signs of bleeding, and was discharged home on
hospital day 19. On hospital day 5, the patient’s
international normalized ratio (INR) was 1.8
(see Fig. 3 for trend) with a PTT of 46.9 s, at
which time an unfractionated heparin infusion
was started for stroke prevention secondary to
atrial fibrillation given a CHA2DS2-VASc score of
5 (indicating a high yearly risk of stroke), and
concern that the patient was unable to reliably
take oral medications in the setting of acute
illness and deconditioning. However, the
patient regained ability to take oral
medications more quickly than anticipated
and was, therefore, started on warfarin on
hospital day 7. On the day of discharge, the Cr
was 0.70 mg/dL (eGFR C60 mL/min/1.73 m2)
with a PTT of 41.3 s and INR of 1.8 on warfarin.
The ALT and AST were last measured on
hospital day 10 at 271 and 32 U/L, respectively.
DISCUSSION
Monitoring of Anticoagulant Assays
There is no established laboratory method for
monitoring dabigatran’s activity. While its
short half-life and reliable pharmacokinetics
render this unnecessary for routine clinical
use, it may be advantageous in the setting of a
potential overdose or clinically significant
bleeding. PT/INR, activated partial
thromboplastin time (aPTT), thrombin clotting
time (TT), ecarin clotting time (ECT), activated
clotting time (ACT), and fibrinogen tests have
all been evaluated as potential measures of the
anticoagulant effect of dabigatran.
While monitoring of the PT/INR is standard
for warfarin therapy, it is relatively insensitive
Table 1 Selected initial laboratory results
Test Result Reference
range
Sodium (mmol/L) 137 135–145
Potassium (mmol/L) 6.6 3.4–5.0
Chloride (mmol/L) 100 98–107
Total CO2 (mmol/L) 10 22–31
Blood urea nitrogen (mg/dL) 45 6–23
Creatinine (mg/dL) 3.05 0.50–1.20
Glucose (mg/dL) 102 70–100
Magnesium (mg/dL) 2.6 1.7–2.6
ALT (U/L) 546 10–50
AST (U/L) 422 10–50
Alkaline phosphatase (U/L) 111 35–130
Total bilirubin (mg/dL) 1.4 0.0–1.0
Direct bilirubin (mg/dL) 0.5 0.0–0.3
CK (U/L) 170 39–308
CKMB (ng/mL) 5.9 0.0–6.6
Troponin T (ng/mL) 0.08 0.00–0.00
NT-proBNP (pg/mL) 3,695 0–1,799
White blood cell count (K/lL) 18.52 4–10
Hemoglobin (g/dL) 14.0 13.5–18.0
Hematocrit (%) 43.5 40–54
Platelet count (K/lL) 214 150–450
PT (s) 54.4 12.2–14.6
PTT (s) 100.6 23.8–36.6
INR 6.0 0.9–1.1
Fibrinogen (mg/dL) 279 200–450
Diluted TT (s) 125.0 (at 24 h)
113.1 (at 26 h)
15–30
ALT alanine aminotransferase, AST aspartate aminotransferase, CK
creatine kinase, CKMB creatine kinase myocardial band, INR
international normalized ratio, NT-proBNP N-terminal prohormone
of brain natriuretic peptide, PT prothrombin time, PTT partial
thromboplastin time, TT thrombin time
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to dabigatran’s effect at therapeutic levels [3–5].
In contrast, the aPTT increases in a curvilinear
fashion with increasing dabigatran
concentration, but the concentration-response
curve plateaus at dabigatran concentrations
above 200 ng/mL [3–7], which is close to the
peak therapeutic level achieved by most
patients [8]. Thus, the aPTT is a sensitive test
for detecting dabigatran activity, but its value
may not accurately reflect dabigatran
concentrations above therapeutic levels.
Similarly, in vitro studies show a linear
relationship between the ACT and dabigatran
concentrations up to 250 ng/mL, with a
flattening of the concentration-response curve
above 500 ng/mL [3]. However, the ACT has
not been systematically tested in patients
and, therefore, its clinical utility remains
uncertain.
The TT directly assesses thrombin activity
and exhibits a linear relationship with
increasing dabigatran concentration up to
600 ng/mL, at which point the value generally
exceeds the maximum measurement time of
most coagulometers [3, 6]. Thus, the standard
TT may be most useful in determining the
presence or absence of circulating dabigatran,
but may be too sensitive for overdose
evaluations [3–5, 7, 9]. The HemoClot
thrombin inhibitor assay (Hyphen BioMed,
Neuville-sur-Oise, France) is not yet
commercially available in the US, but holds
promise as a useful assay for determining drug
concentration [3, 4, 7, 9]. The diluted TT assay
exhibits a linear relationship with dabigatran
concentrations, even at high levels. Thus,
dabigatran standards can be supplied to run a
calibration curve and thereby determine plasma
dabigatran concentration. The ECT is another
promising assay of thrombin generation that
exhibits a linear relationship with plasma
concentrations of dabigatran [3, 5]. However,
ECT is currently only available in the research
setting [9] and was not available at the authors’
institution.
Fig. 3 Coagulation parameters, creatinine and liver
enzymes over time. 2 units (total 400 cc) of FFP and
5 mg of oral vitamin K were administered at arrow 1; 5,020
international units of Proﬁlnine, 2 units of FFP and
10 mg of intravenous vitamin K were administered at arrow
2; 2 units of FFP were administered at arrow 3 (prior to
central venous catheter placement). Thrombin time was
measured (not shown) at hours 7, 24, and 26 and remained
[150 s and the diluted TT was 125.0 and 113.1 s at 24 and
26 h, respectively. Of note, 8 months prior to admission the
PT and international normalized ratio were 25.2 and 1.1,
respectively. PTT partial thromboplastin time, ALT
alanine aminotransferase, AST aspartate aminotransferase,
Cre creatinine, FFP fresh frozen plasma, PT prothrombin
time, TT thrombin clotting time
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Dabigatran was developed with the
expectation that routine laboratory
monitoring of its anticoagulant effect would
not be needed. However, the present patient’s
case demonstrates the utility of adopting
standardized testing to determine plasma
dabigatran concentration. Although initial
fibrinogen concentration was in the normal
range at 279 mg/dL, the presence of hepatic
failure in the present patient made it difficult to
determine the degree of coagulopathy
attributable to dabigatran versus the
contribution from impaired hepatic synthetic
function.
Use of Dabigatran in Elderly Patients
Numerous case reports of serious bleeding on
dabigatran have been reported in the elderly
[7, 10–16]. As in the present patient, these events
are frequently precipitated by development of
acute renal failure. In patients with normal renal
function, dabigatran’s half-life is 12–17 h [12].
In patients with a creatinine clearance (CrCl)
between 30–50 mL/min, the half-life increases
to 13–23 h [12]. As the CrCl falls below
30 mL/min, dabigatran’s half-life increases to
22–35 h [12]. For patients with a baseline CrCl of
15–30 mL/min or CrCl of 30–50 mL/min
receiving concomitant treatment with strong
inhibitors of P-glycoprotein (P-gp), the FDA has
approved a dabigatran dose of 75 mg twice-daily
[17]. Of note, the RE-LY trial excluded patients
with a CrCl less than 30 mL/min and, thus, both
the efficacy and relative bleeding risk as
compared with warfarin have not been
established in this population [1].
Although several case reports implicate
development of acute renal failure as the cause
for excessive anticoagulation with dabigatran
use in the elderly, there are no established
guidelines for monitoring renal function while
on dabigatran [10–12]. The Italian Federation of
Thrombosis Centers recommends annual
assessment of renal function in patients with
mild renal failure and bi-annual assessments in
patients with moderate renal failure [18]. In
November of 2011, the prescribing information
for dabigatran was revised to recommend
calculation of CrCl prior to drug initiation, in
any clinical situation potentially associated
with a decline in renal function, and annual
monitoring in patients greater than 75 years of
age or with a CrCl less than 50 mL/min [12, 19].
Close monitoring of CrCl may enable detection
of asymptomatic changes in renal function that
warrant dose adjustments or cessation of the
drug.
In an analysis from the RE-LY trial, patients
aged less than 75 years experienced less
bleeding with both dabigatran 110 and 150 mg
as compared to warfarin (1.89% versus 3.04%,
P\0.001 for 110 mg; 2.12% versus 3.04%,
P\0.001 for 150 mg) [20]. Among patients
aged 75 years and older, however, the risk of
bleeding with dabigatran 110 mg was similar to
that of warfarin (4.43% versus 4.37%, P = 0.89),
but a trend toward increased risk of bleeding
with age emerged with dabigatran 150 mg as
compared with warfarin (5.10% versus 4.37%,
P = 0.07; P for interaction \0.001) [20]. When
the type of bleeding was further analyzed, an
increased risk of extracranial bleeding with age
emerged, but the risk of intracranial bleeding
remained lower for dabigatran as compared
with warfarin regardless of age [20].
Interestingly, patients with CrCl \50 mL/min
experienced a more than twofold increased risk
of major bleeding with both dabigatran and
warfarin as compared to patients with CrCl
C80 mL/min even though warfarin, unlike
dabigatran, is not renally excreted [20]. Given
a lack of association between treatment and
CrCl with major bleeding, factors other than a
Cardiol Ther (2013) 2:111–124 117
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tendency toward impaired renal function may
contribute to the increased risk of extracranial
bleeding that elderly patients experience with
dabigatran therapy [20].
Because dabigatran is not metabolized by the
cytochrome (CYP) P450 system, drugs affecting
CYP enzymes should not affect dabigatran
[5, 21]. Dabigatran is, however, a substrate of
the efflux transporter P-gp [17]. Inducers of P-gp
(e.g., rifampin) decrease peak dabigatran
concentrations, while P-gp inhibitors (e.g.,
ketoconazole and dronedarone) increase peak
concentrations. This latter interaction is of
particular importance in patients with renal
impairment in whom dose adjustments of
dabigatran or avoidance of the P-gp inhibitor
should be considered depending on the specific
co-administered drug and degree of renal
impairment [5, 17, 21]. Of note, no dose
adjustment of dabigatran is recommended in
combination with moderate P-gp inhibitors
(e.g., verapamil, amiodarone, quinidine, and
clarithromycin) [17].
Methods for Reversal of Dabigatran’s
Anticoagulant Effect
Reports of major bleeding in patients receiving
dabigatran have garnered attention in large
part due to the fact that, unlike warfarin, there
is currently no antidote for its anticoagulant
effect. Given its relatively short half-life
(12–17 h) compared to vitamin K antagonists,
drug cessation and supportive care is often
sufficient in patients with normal renal
function who will excrete the drug within
hours [3, 10, 12, 14, 22]. By 12 h, dabigatran
plasma concentrations fall below 100 ng/mL
and aPTT falls to 1.5 times baseline values in
patients with normal renal function taking
150 mg of dabigatran twice-daily [3]. Even with
impaired CrCl, promoting diuresis when
possible is encouraged as a means of
eliminating the drug [7]. As shown in Fig. 3,
the present patient’s coagulation parameters
improved in conjunction with improving renal
function. When overdose is suspected,
dabigatran can be absorbed by activated
charcoal given within 1–2 h of ingestion,
although this has only been tested in vitro
[3, 6, 23]. However, case reports of dabigatran
overdose cite new renal failure rather than
either intentional or accidental ingestion as
the usual culprit, limiting the utility of this
potential method [12, 13, 15, 16].
Many therapies used to reverse other
anticoagulants are ineffective with dabigatran.
Vitamin K and protamine sulfate, well-known
antidotes of warfarin and heparin, respectively,
are not beneficial for over-anticoagulation with
dabigatran [3, 22]. Use of cryoprecipitate has
been cited in two case reports without clinical
benefit [16, 24]. While the 2011 focused update
on the management of patients with atrial
fibrillation (update on dabigatran) from the
American College of Cardiology, American
Heart Association, and Heart Rhythm Society
suggest the use of FFP, many cases report
utilization of FFP without a significant change
in the aPTT or INR [3, 6, 22, 23, 25].
Recombinant activated factor VII (rFVIIa)
was developed for treatment of bleeding in
hemophiliac patients with inhibitors to factors
VIII and IX. Exogenous factor VIIa can directly
activate thrombin on the surface of platelets in
the absence of tissue factor and has, therefore,
gained interest as a potential means of reversing
dabigatran’s effect [3, 6, 23]. However, rFVIIa
did not reverse the antithrombotic effects of
melagatran (the active form of the oral direct
thrombin inhibitor, ximelagatran, which is not
available for clinical use) in a single-blind,
randomized study of 47 healthy male
volunteers [26].
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In an ex vivo study of eight patients with
atrial fibrillation taking dabigatran 150 mg
twice-daily, Davis et al. [27] investigated the
Rapid Thromboelastographic-derived activated
clotting time (RapidTEG-ACT) as a method of
measuring both the anticoagulant activity of
dabigatran and the potential for reversibility
with human inactivated thrombin (HTI),
rFVIIa, and a four-factor PCC. In concert with
aPTT, PT, TT, and ACT, measurement of
reaction time from test initiation to initial
fibrin formation using thromboelastography
(called the TEG R-value) is a potentially useful
laboratory value for assessing dabigatran’s
anticoagulant activity. The addition of HTI
(currently only available topically and,
therefore, unsuited for in vivo testing for this
indication) and rFVIIa to patients’ peripheral
blood significantly reduced the TEG R-value
while the PCC analog did not. This study
suggests a potential utility for rFVIIa that
requires further investigation in vivo and
clinically.
In a case report of a 79-year-old participant
in the RE-LY trial who unintentionally
underwent cardiac surgery with therapeutic
levels of circulating dabigatran, the authors
reported initially trying three doses of
2.4 mg/dose of rFVIIa without success in
controlling the patient’s post-operative bleeding
[24]. The authors subsequently administered two
doses of 7.2 mg/dose and, although they did not
report coagulation parameters, they cited a
reduction in the patient’s bleeding as a
favorable sign that high-dose rFVIIa may
reduce dabigatran-associated bleeding.
However, the patient also underwent
hemodialysis (HD), which may have
contributed to the reduction in bleeding.
Furthermore, given the potential of rFVIIa to
precipitate myocardial infarction and stroke,
care should be taken in using rFVIIa for bleeding
events in non-hemophiliacs. The FDA has
issued a black box warning due to an increased
potential for thrombotic events when rVIIa is
used outside of the product’s approved
indications [28].
Several cases reports, including the present,
have commented on the utilization of PCC, of
which there are two types available [12, 23]. In
the US, only three-factor concentrates are
available. They contain II, IX, and X but very
low levels of VII. Profilnine is a three-factor PCC
used in the authors’ institution. Cofact
(Sanquin, Amsterdam, The Netherlands) is a
four-factor PCC that contains higher levels of
factor VII and is available in Canada and several
European countries. In a randomized, double-
blind trial of 12 healthy male volunteers,
50 IU/kg of Cofact did not reverse the
anticoagulant effects of dabigatran as
measured using aPTT, ECT, or TT [29]. In the
present case, the patient’s coagulopathy did
rapidly correct, but the independent
contribution of Profilnine could not be
determined as it was administered concomitantly
with vitamin K and FFP (Fig. 3).
An activated PCC (aPCC) available in the US
is Factor Eight Inhibitory Bypassing Activity
(FEIBA; FEIBA NF, Baxter, West Lake Village,
CA, USA). This product is an aPCC concentrate
containing factors II, activated VII, IX, and X
that was developed for hemophiliac patients
with inhibitors to factors VIII or IX. FEIBA has
the theoretical benefit of combining the effects
of rFVIIa and PCC [23, 30]. In vitro, FEIBA
decreased the aPTT of plasma containing factor
VIII inhibitor [30]. Marlu et al. [31] assessed
whether PCC, rFVIIa, or FEIBA could reverse the
anticoagulant effect of dabigatran 150 mg
in vitro using venous blood from ten, healthy,
white male patients. Four-factor PCC and FEIBA
increased the endogenous thrombin potential
of dabigatran-anticoagulated plasma, with low
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doses successfully reducing levels back to
baseline and regular or half doses actually
increasing thrombin generation. The highest
dose of rFVIIa (3 U/mL) and the three highest
doses of FEIBA (0.5–2 U/mL) corrected lag time
in thrombin generation nearly to baseline. This
study suggests that these products remain
promising with respect to reversal of
dabigatran-induced thrombin inhibition.
Finally, a number of novel reversal agents are
currently in various stages of development. Van
Ryn et al. [32] reported that a humanized
monoclonal antibody fragment (Fab) against
dabigatran can completely inhibit the
anticoagulant activity of the drug in both
human plasma and whole blood. A synthetic
small molecule, PER977, is being developed as a
potential antidote to all novel oral
anticoagulant drugs, with activity against
factor Xa and IIa inhibitors [33]. In addition, a
truncated, inactive form of factor Xa known as
PRT064445 is currently being tested in phase 2
clinical trials. Early in vitro and in vivo studies
have shown this compound to be an effective
reversal agent for both the newer direct factor
Xa inhibitors and indirect factor Xa inhibitors,
such as low molecular weight heparin and
fondaparinux [33–36].




66-year-old woman (CrCl *15 mL/min) with
upper GI bleeding
Four sessions of HD over 5 days resulted in
resolution of bleeding, decrease in INR from 2.2 to
1.3, decrease in aPTT from 74.7 to 34.8, no change
in corrected TT from[60 s
Maddry
et al. [13]
74-year-old man (Cr 3.1 mg/dL) with hematemesis After 4 h of HD, the dabigatran level decreased from
370 to 130 ng/mL
Louet et al.
[15]
86-year-old man (CrCl 13.8 mL/min) with GI
bleeding
6 h of HD resulted in 60% drug removal
Warkentin
et al. [24]
79-year-old man (CrCl 36 mL/min) underwent
cardiac surgery with therapeutic dabigatran levels
and suffered severe post-op bleeding
After 6 h of high-ﬂux dialysis, the dabigatran level
decreased from 76 to 27 ng/mL
Harinstein
et al. [16]
84-year-old man (CrCl 25 mL/min) with GI and
surgical site bleeding
After 51 h of continuous renal replacement therapy
(HD could not be performed due to hemodynamic
instability) TT dropped from[120 to 109.7 s
Wanek et al.
[37]
59-year-old woman (CrCl 40 mL/min) presented for
cardiac transplant 36 h after last dabigatran dose
After 1 h of HD, TT decreased from 90.6 to 65.6 s;
after 2.5 h, TT decreased to 60.2 s
Chang et al.
[38]
94-year-old man with normal renal function
presented with a subdural hematoma
After 1 h of HD, the dabigatran level was 49 ng/mL;
after 2 h, the dabigatran level was 20 ng/mL.
Dabigatran levels rebounded after dialysis cessation,
causing the authors to suggest a longer duration of
therapy for future cases
aPTT activated partial thromboplastin time, ARF acute renal failure, CrCl creatinine clearance, GI gastrointestinal, HD
hemodialysis, INR international normalized ratio, TT thrombin clotting time
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Use of HD in the Management of Severe
Bleeding with Dabigatran
Given its lipophilic structure and the fact that a
large fraction is not protein bound, up to 62%
of plasma dabigatran levels can be removed over
2 h of HD [13, 22, 30]. Several case reports have
explored this modality and consistently
reported reductions in dabigatran levels with
HD (Table 2) [12, 15, 16, 21, 23, 24, 37, 38].
While evidence in support of HD is limited to
case reports, the consistently cited benefit of
this modality makes it a promising treatment
option in cases of dabigatran-associated
bleeding. Given the bleeding risk associated
with placing a dialysis catheter in a patient with
severe coagulopathy, other methods to reverse
the anticoagulant effect of dabigatran will be
necessary complements to a treatment strategy
incorporating HD. In addition, although
typically utilized for patients experiencing
bleeding in the setting of acute renal failure, it
is possible that HD confers a benefit over
supportive therapy and promotion of diuresis
in patients presenting with bleeding in the
context of normal renal function.
Elevations in Liver Enzymes with Oral
Direct Thrombin Inhibitors
The first developed oral direct thrombin
inhibitor, ximelagatran, was associated with
ALT elevations in 6.4% of patients (as
compared to 1.2% taking placebo) [39]. Some
patients developed clear evidence of drug-
induced liver injury (occasionally fatal),
resulting in removal of the drug from the
European market [39–41] (ximelagatran was
never approved for use in the US). However,
dabigatran has not been associated with an
increased rate of liver function abnormalities in
the RE-LY trial or in other studies of venous
thromboembolism prevention and treatment
[1, 42]. The present patient presented with
elevations of both ALT and AST in a clinical
context, most suggestive of hepatic
hypoperfusion. However, the authors cannot
exclude a direct toxic effect of dabigatran.
CONCLUSION
The authors present a case of an elderly
gentleman on dabigatran 150 mg twice-daily
who developed a significant coagulopathy in
the setting of acute renal and hepatic failure.
Given that numerous case reports involving
elderly patients implicate fluctuations in renal
function as a precursor to adverse bleeding
events, it is important for clinicians to
carefully follow renal function in older
patients on dabigatran. Although routine
monitoring of dabigatran’s anticoagulant
effect is not required, a better understanding
and availability of laboratory tests specific for
dabigatran activity would prove beneficial in
managing adverse bleeding events. Finally, a
means of reliably and safely reversing the
anticoagulant effects of dabigatran will be
crucial in effectively managing bleeding in
patients taking this medication. While
dabigatran carries an equal or lower rate of
bleeding compared to warfarin, bleeding events
on dabigatran will continue to pose a clinical
challenge until optimal monitoring tests and
reversal strategies are better defined.
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